After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? (Q46822559)

25 December 2017

title

After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? (English)

1 reference

25 December 2017

main subject

cardiovascular disease

1 reference

1

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

25 December 2017

published in

The Lancet

1 reference

25 December 2017

volume

366

1 reference

25 December 2017

issue

9500

1 reference

25 December 2017

page(s)

1829-1831

1 reference

25 December 2017

Diabetic dyslipidaemia: from basic research to clinical practice.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by i

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

Standards of medical care in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

Efficacy of Gemfibrozil in Dyslipidaemic Subjects with Suspected Heart Disease. An Ancillary Study in the Helsinki Heart Study Frame Population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967668-4

7 January 2021

10.1016/S0140-6736(05)67668-4

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wbgcbudh5bba5ki2yb2g35nfbi

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_wbgcbudh5bba5ki2yb2g35nfbi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wbgcbudh5bba5ki2yb2g35nfbi

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/wbgcbudh5bba5ki2yb2g35nfbi

30 July 2022